Therapy of Ischemic Cerebral Vascular Disease

Martin M. Pincus, Michael Hennerici, Wolfgang Rautenberg, Lawrence J. Saidman, J. P. Kistler, Allan H. Ropper, Roberto Heros

Research output: Contribution to journal › Letter

2 Scopus citations

Abstract

To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

Original language	English (US)
Pages (from-to)	1124-1125
Number of pages	2
Journal	New England Journal of Medicine
Volume	311
Issue number	17
DOIs	https://doi.org/10.1056/NEJM198410253111715
State	Published - Oct 25 1984
Externally published	Yes

Fingerprint

ASJC Scopus subject areas

Medicine(all)

Cite this

Therapy of Ischemic Cerebral Vascular Disease. / Pincus, Martin M.; Hennerici, Michael; Rautenberg, Wolfgang; Saidman, Lawrence J.; Kistler, J. P.; Ropper, Allan H.; Heros, Roberto.

In: New England Journal of Medicine, Vol. 311, No. 17, 25.10.1984, p. 1124-1125.

Research output: Contribution to journal › Letter

@article{fcc46849c0694dcb8d6a657c4368cfae,

title = "Therapy of Ischemic Cerebral Vascular Disease",

abstract = "To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.",

author = "Pincus, {Martin M.} and Michael Hennerici and Wolfgang Rautenberg and Saidman, {Lawrence J.} and Kistler, {J. P.} and Ropper, {Allan H.} and Roberto Heros",

year = "1984",

month = oct

day = "25",

doi = "10.1056/NEJM198410253111715",

language = "English (US)",

volume = "311",

pages = "1124--1125",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - Therapy of Ischemic Cerebral Vascular Disease

AU - Pincus, Martin M.

AU - Hennerici, Michael

AU - Rautenberg, Wolfgang

AU - Saidman, Lawrence J.

AU - Kistler, J. P.

AU - Ropper, Allan H.

AU - Heros, Roberto

PY - 1984/10/25

Y1 - 1984/10/25

N2 - To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

AB - To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

UR - http://www.scopus.com/inward/record.url?scp=0021150084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021150084&partnerID=8YFLogxK

U2 - 10.1056/NEJM198410253111715

DO - 10.1056/NEJM198410253111715

M3 - Letter

C2 - 6482925

AN - SCOPUS:0021150084

VL - 311

SP - 1124

EP - 1125

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -

Access to Document

10.1056/NEJM198410253111715